Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus

Authors: Zaid Al-Hamodi, Molham AL-Habori, Ali Al-Meeri, Riyadh Saif-Ali

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Objective

Alterations in plasma adipokines and/or inflammatory parameters in Type 2 DM remain vague as to whether they are due to obesity and/or directly associated with the diabetic state. Our objective was to compare plasma adiponectin, leptin, leptin/adiponectin ratio (LAR) and hs-CRP in obese non-diabetic subjects and non-obese Type 2 DM patients, as well as determining the association of these adipokines with MetS and diabetes-related quantitative traits.

Methods

In this study, 92 Yemeni male volunteers aged 25–60 years old were enrolled, 31 of whom were healthy subjects with BMI < 25 kg/m2 served as control; 30 non-diabetic obese subjects BMI ≥ 30 kg/m2 and FBG < 6.1 mmol/l; and 31 non-obese Type 2 DM with FBG > 7 mmol/l and BMI < 25 kg/m2.

Results

Adiponectin was lower in obese subjects, with no differences between non-obese Type 2 DM patients and controls. In contrast, leptin, LAR and hs-CRP were higher in both obese subjects and non-obese Type 2 DM patients. Linear regression analysis showed adiponectin to be associated negatively with BMI, waist circumference, insulin, HOMA-β and HOMA-IR; whereas leptin, LAR and hs-CRP were associated positively with BMI, waist circumference, TG, FBG, insulin, HOMA-β and HOMA-IR. Moreover, adiponectin negatively correlated with leptin, LAR and hs-CRP; whereas leptin and LAR positively correlated with hs-CRP and with each other.

Conclusion

Plasma adiponectin is not affected by diabetes per se, suggesting that its alterations in Type 2 DM may be due to obesity and may be an important link between adiposity, IR and Type 2 DM.
Literature
1.
Stumvoll M, Goldstein B, van Haeften T: Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005, 365: 1333-1346. 10.1016/S0140-6736(05)61032-X.CrossRefPubMed
2.
Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction in the pathophysiology of type 2 diabetes. Diabetologia. 2008, 46: 3-19.
3.
4.
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006, 17: 4-12.PubMed
5.
6.
Badawi A, Klip A, Haddad P, Cole D, Garcia Bailo B, El-Sohemy A, Karmali M: Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diab Metab Syndr Obesity: Targets and Therapy. 2010, 3: 173-186.CrossRef
7.
Donath MY, Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011, 11: 98-107. 10.1038/nri2925.CrossRefPubMed
8.
Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, Rentfro A, McCormick JB, Fisher-Hoch SP: Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012, 57 (1): 136-142. 10.1016/j.cyto.2011.09.029.PubMedCentralCrossRefPubMed
9.
Calle MC, Fernandez ML: Inflammation and type 2 diabetes. Diabetes Metab. 2012, 38 (3): 183-191. 10.1016/j.diabet.2011.11.006.CrossRefPubMed
10.
King GL: The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008, 79: 1527-1534. 10.1902/jop.2008.080246.CrossRefPubMed
11.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006, 116: 1784-1792. 10.1172/JCI29126.PubMedCentralCrossRefPubMed
12.
Turer AT, Scherer PE: Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012, 55: 2319-2326. 10.1007/s00125-012-2598-x.CrossRefPubMed
13.
Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007, 92: 1023-1033. 10.1210/jc.2006-1055.CrossRefPubMed
14.
Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H, Bredahl R, Hahnloser E, Martin S: Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab. 2007, 92: 4569-4574. 10.1210/jc.2007-0955.CrossRefPubMed
15.
Saltevo J, Laakso M, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M: Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population based study. Diabetes Metab Res Rev. 2008, 24: 378-383. 10.1002/dmrr.831.CrossRefPubMed
16.
Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Hegele RA, Retnakaran R, Zinman B, Hanley AJG: Adipokines and incident type 2 diabetes in an aboriginal Canadian [corrected] population: the Sandy Lake health and diabetes project. Diabetes Care. 2008, 31: 1410-1415. 10.2337/dc08-0036.PubMedCentralCrossRefPubMed
17.
Tabak AG, Brunner EJ, Miller MA, Karanam S, Mc Ternan PG, Cappuccio FP, Witte DR: Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res. 2009, 41: 626-629. 10.1055/s-0029-1216359.PubMedCentralCrossRefPubMed
18.
Kishida K, Funahashi T, Shimomura I: Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocrine Metab Immune Disor - Drug Targets. 2012, 12: 118-131. 10.2174/187153012800493468.CrossRef
19.
Ohashi K, Ouchi N, Matsuzawa Y: Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012, 94: 2137-2142. 10.1016/j.biochi.2012.06.008.CrossRefPubMed
20.
Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P: Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol. 2006, 65: 722-728. 10.1111/j.1365-2265.2006.02658.x.CrossRef
21.
Miazgowski T, Dziwura-Ogonowska J, Safranow K, Iskierska K, Widecka K: Changes in adiponectin level and fat distribution in patients with type 2 diabetes. Eur J Clin Invest. 2014, 44 (2): 192-199. 10.1111/eci.12207.CrossRefPubMed
22.
Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni A, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002, 360: 57-58. 10.1016/S0140-6736(02)09335-2.CrossRefPubMed
23.
Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R: Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. Diabetes. 2008, 57: 980-986. 10.2337/db07-1419.PubMedCentralCrossRefPubMed
24.
Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W: Associations between leptin and the leptin/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg Study 1984–2002. Diabetic Med. 2010, 27: 1004-1011. 10.1111/j.1464-5491.2010.03043.x.CrossRefPubMed
25.
Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R: Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Preventive Cardiol. 2013, published online 21 November
26.
Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, Gualillo O: Leptin, from fat to inflammation: Old questions and new insights. FEBS Lett. 2005, 579: 295-301. 10.1016/j.febslet.2004.11.024.CrossRefPubMed
27.
Farooqi IS, O’Rahilly S: Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr. 2009, 89: 980S-984S. 10.3945/ajcn.2008.26788C.CrossRefPubMed
28.
Myers MG, Cowley MA, Munzberg H: Mechanisms of leptin action and leptin resistance. Ann Rev Physiol. 2008, 70: 537-556. 10.1146/annurev.physiol.70.113006.100707.CrossRef
29.
Martin SS, Qasim A, Reilly MP: Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008, 52: 1201-1210. 10.1016/j.jacc.2008.05.060.PubMedCentralCrossRefPubMed
30.
Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G: Leptin and incident type 2 diabetes: risk or protection?. Diabetologia. 2006, 49: 2086-2096. 10.1007/s00125-006-0351-z.CrossRefPubMed
31.
Abdelgadir M, Elbagir M, Eltom M, Berne C, Ahrén B: Reduced leptin concentrations in subjects with type 2 diabetes mellitus in Sudan. Metabolism. 2002, 51: 304-306. 10.1053/meta.2002.30504.CrossRefPubMed
32.
Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S: The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high-sensitivity c-reactive protein levels. Is adipocyte size associated with inflammation in adults?. J Endocrinol Invest. 2007, 30: 210-214. 10.1007/BF03347427.CrossRefPubMed
33.
Lilja M, Rolandsson O, Norberg M, Soderberg S: The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance. Metab Syndr Relat Disord. 2012, 10: 143-151. 10.1089/met.2011.0123.CrossRefPubMed
34.
Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI: Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism. 2004, 53 (11): 1454-1461. 10.1016/j.metabol.2004.06.013.CrossRefPubMed
35.
Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F, Hong J, Gu Y, Li X, Ning G, Chen M: Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract. 2006, 72 (3): 244-250. 10.1016/j.diabres.2005.10.025.CrossRefPubMed
36.
Neuparth MJ, Proença JB, Santos-Silva A, Coimbra S: Adipokines, oxidized low- density lipoprotein, and C-reactive protein levels in lean, overweight, and obese Portuguese patients with type 2 diabetes. Obesity. 2013, Article ID 142097
37.
Hansen D, Dendale P, Beelen M, Jonkers RAM, Mullens A, Corluy L, Meeusen R, van Loon LJC: Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol. 2010, 109: 397-404. 10.1007/s00421-010-1362-5.PubMedCentralCrossRefPubMed
38.
Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T: Adiponectin as a biomarker of the metabolic syndrome. Circulation J. 2004, 68: 975-981. 10.1253/circj.68.975.CrossRef
39.
Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A: Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obesity. 2007, 31: 213-220. 10.1038/sj.ijo.0803355.CrossRef
40.
Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA: The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res. 2009, 37: 1803-1812. 10.1177/147323000903700616.CrossRefPubMed
41.
Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the pima Indian. Diabetes Care. 2003, 26: 1745-1751. 10.2337/diacare.26.6.1745.CrossRefPubMed
42.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3 T3-L1 adipocytes. Biochem Biophys Res Commun. 2002, 290: 1084-1089. 10.1006/bbrc.2001.6307.CrossRefPubMed
43.
Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J: Insulin decreases human adiponectin plasma levels. Horm Metab Res. 2002, 34: 655-658. 10.1055/s-2002-38248.CrossRefPubMed
44.
Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R: Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3 T3-L1 adipocytes. Biochem Biophys Res Commun. 2003, 301: 1045-1050. 10.1016/S0006-291X(03)00090-1.CrossRefPubMed
45.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto M, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Ya-mashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose- specific protein, adiponectin, in type 2 diabetic patients. Arterio Thromb Vascul Biol. 2000, 20: 1595-1599. 10.1161/01.ATV.20.6.1595.CrossRef
46.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive- leptin concentration in normal weight and obese humans. N Engl J Med. 1996, 334: 292-295. 10.1056/NEJM199602013340503.CrossRefPubMed
47.
Park K-G, Park KS, Kim M-J, Kim H-S, Suh Y-S, Ahn JD, Park K-K, Chang Y-C, Lee I-K: Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004, 63 (2): 135-142. 10.1016/j.diabres.2003.09.010.CrossRefPubMed
48.
Tajtakova M, Petrasova D, Pidanicova A, Gallovicova A, Blanarova C, Petrovicova J: Serum levels of leptin, adiponectin, retinol binding protein 4 and leptin/adiponectin molar ratio as another possible marker of insulin resistance in obese. Bratisl Lek Listy. 2010, 111: 212-215.PubMed
49.
Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, Kuzuya H, Shimatsu A, Ogawa Y: Leptin to adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care. 2004, 27: 2488-2490. 10.2337/diacare.27.10.2488.CrossRefPubMed
50.
Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB: Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care. 2004, 27: 1680-1687. 10.2337/diacare.27.7.1680.CrossRefPubMed
51.
Marques-Vidal P, Bastardot F, von Kanel R, Paccaud F, Preisig M, Waeber G, Vollenweider P: Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol. 2013, 78: 232-241. 10.1111/j.1365-2265.2012.04384.x.CrossRef
52.
Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, Liu LG: Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013, 36 (1): 166-175. 10.2337/dc12-0702.PubMedCentralCrossRefPubMed
53.
Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W, Brook GJ, Levy Y: Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabetic Med. 2004, 21 (1): 39-44. 10.1046/j.1464-5491.2003.01084.x.CrossRefPubMed
54.
Choi J, Joseph L, Pilote L: Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obesity Rev. 2013, 14: 232-244. 10.1111/obr.12003.CrossRef
55.
Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M: Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism. 2002, 51: 743-749. 10.1053/meta.2002.32804.CrossRefPubMed
56.
Chou HH, Hsu LA, Liu CJ, Teng MS, Wu S, Ko YL: Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. Metabolism. 2010, 59 (6): 824-830. 10.1016/j.metabol.2009.09.030.CrossRefPubMed
57.
Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM: C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol. 2003, 23: 650-655. 10.1161/01.ATV.0000065636.15310.9C.CrossRefPubMed
Metadata
Title
Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus
Authors
Zaid Al-Hamodi
Molham AL-Habori
Ali Al-Meeri
Riyadh Saif-Ali
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-99

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue

Research

Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study

Research

Individuals with prediabetes identified by HbA1c undergoing coronary angiography have worse cardiometabolic profile than those identified by fasting glucose

Research

High prevalence of diabetes and intermediate hyperglycemia – The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

Research

Precocious markers of cardiovascular risk and vascular damage in apparently healthy women with previous gestational diabetes

Research

Correlation between reduction of superior interventricular groove epicardial fat thickness and improvement of insulin resistance after weight loss in obese men

Research

Supplementary use of HbA1c as hyperglycemic criterion to detect metabolic syndrome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits